Amivantamab in advanced non-small cell lung cancer with epidermal growth factor receptor exon 20 insertion mutations: Real-world data from the Italian ATLAS Registry.
Summary
This retrospective observational study, conducted using the Italian ATLAS Registry, evaluated the efficacy and safety of amivantamab in 119 patients with advanced non-small cell lung cancer (NSCLC) harboring EGFR exon 20 insertion mutations. Most patients had previously received platinum-based chemotherapy, with or without immunotherapy. Amivantamab, administered as a single agent in subsequent lines, demonstrated an objective response rate of 37.5%, a median progression-free survival of 9.6 months, and a median overall survival of 16.9 months. The safety profile was manageable, with grade 3-4 treatment-related adverse events reported in 10.9% of patients, confirming data from the CHRYSALIS trial in a heavily pretreated real-world population.
Analysis
This study holds significant clinical importance as it provides real-world data confirming the efficacy and safety of amivantamab for patients with advanced NSCLC harboring EGFR exon 20 insertion mutations, a challenging-to-treat population. The validation of these results in a routine clinical practice setting, involving heavily pretreated patients, strengthens confidence in amivantamab as a new standard of care. These data are crucial for clinicians, as they support the integration of this targeted therapy into treatment algorithms and help manage patient expectations regarding benefits and side effects.